Samsung Bioepis Obtains First Drug Approval in the United States as the U.S. Food and Drug Administration Approves RENFLEXIS Infliximababda Across All Eligible Indications

Samsung Bioepis Co. Ltd. today announced that the U.S. Food and Drug Administration FDA has approved RENFLEXIS infliximababda a biosimilar referencing RemicadeÂi infliximab across all eligible indications. In the US RENFLEXIS is ind...